CagriSema: difference between revisions
Diff·revision 8 → 9·06:11, 27 Jan 2025
Difference between revision 8 and revision 9 of CagriSema. 1 line changed; the page grew by 74 bytes.
| Revision 8 — 02:11, 3 Jan 2025 OrforglipronOona (talk) state plainly that the research-use-only form is not approved for human use 2,915 bytes ±0 | Revision 9 — 06:11, 27 Jan 2025 UnderfillUna (talk) add the molecular formula to the infobox 2,989 bytes +74 | ||
|---|---|---|---|
| 6 | | Status = Phase 3; not approved | 6 | | Status = Phase 3; not approved |
| 7 | }} | 7 | }} |
| + | 8 | {{hatnote|For the components, see [[Cagrilintide]] and [[Semaglutide]].}} | |
| 8 | 9 | ||
| 9 | '''CagriSema''' is an investigational fixed-ratio combination of the [[Amylin receptor agonist|amylin analogue]] [[Cagrilintide|cagrilintide]] and the [[GLP-1 receptor agonist]] [[Semaglutide|semaglutide]], co-formulated for weekly subcutaneous administration in a single injection. It is not approved for use in any indication.{{r|frias2023cagri}} | 10 | '''CagriSema''' is an investigational fixed-ratio combination of the [[Amylin receptor agonist|amylin analogue]] [[Cagrilintide|cagrilintide]] and the [[GLP-1 receptor agonist]] [[Semaglutide|semaglutide]], co-formulated for weekly subcutaneous administration in a single injection. It is not approved for use in any indication.{{r|frias2023cagri}} |